AstraZeneca revenues up as it delivers jab to 120 countries via Covax

Quarterly results from Anglo-Swedish producer of Covid vaccine show better-than-expected 15% rise

AstraZeneca has generated $275m (£197m) in revenues from its Covid vaccine in the first three months of the year and shipped 48m doses to 120 countries through the global vaccine-sharing initiative Covax.

Most of the vaccine sales ($224m) were in Europe – as the Anglo-Swedish drugmaker reported overall quarterly revenues up 15% to $7.3bn, better than analysts had expected. New medicines, such as the diabetes drug Farxiga, contributed more than half of revenues. The firm made a pre-tax profit of $1.6bn, up 72% year-on-year.

Continue reading...

Coronavirus | The Guardian

Comments

Popular posts from this blog

NSW Covid update: 65 new cases as GP clinics and pharmacies drive new spread of virus

Covid vaccine used on apes at San Diego zoo trialled on mink

Ministers accused of sowing confusion over England’s travel advice